[
  {
    "ts": "2025-09-17T18:27:07+00:00",
    "headline": "Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00. Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal […]",
    "url": "https://finance.yahoo.com/news/bank-america-securities-maintains-buy-182707900.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "462facb6-9786-35db-9984-b377c8d15dd4",
      "content": {
        "id": "462facb6-9786-35db-9984-b377c8d15dd4",
        "contentType": "STORY",
        "title": "Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00. Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal […]",
        "pubDate": "2025-09-17T18:27:07Z",
        "displayTime": "2025-09-17T18:27:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F08AN_WgfDoxxGlrVQfGRQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ux9OKsmqTigW_m7aYltcpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bank-america-securities-maintains-buy-182707900.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bank-america-securities-maintains-buy-182707900.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-17T13:38:00+00:00",
    "headline": "INCY Announces New Late-Stage Data on Skin Disease Drug",
    "summary": "Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.",
    "url": "https://finance.yahoo.com/news/incy-announces-stage-data-skin-133800277.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "73f6c8df-e778-340c-9ee4-0a70cea0bd4b",
      "content": {
        "id": "73f6c8df-e778-340c-9ee4-0a70cea0bd4b",
        "contentType": "STORY",
        "title": "INCY Announces New Late-Stage Data on Skin Disease Drug",
        "description": "",
        "summary": "Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.",
        "pubDate": "2025-09-17T13:38:00Z",
        "displayTime": "2025-09-17T13:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incy-announces-stage-data-skin-133800277.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incy-announces-stage-data-skin-133800277.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-17T05:00:00+00:00",
    "headline": "Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
    "summary": "WILMINGTON, Del., September 17, 2025--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
    "url": "https://finance.yahoo.com/news/incyte-announces-24-week-phase-050000342.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a009e0e1-c711-3b4d-a32a-5992bc83212b",
      "content": {
        "id": "a009e0e1-c711-3b4d-a32a-5992bc83212b",
        "contentType": "STORY",
        "title": "Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
        "description": "",
        "summary": "WILMINGTON, Del., September 17, 2025--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
        "pubDate": "2025-09-17T05:00:00Z",
        "displayTime": "2025-09-17T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/681def478f12e96d03f36ecb564b368d",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mAOXL1mbQjSrIQx0RVlhWQ--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/681def478f12e96d03f36ecb564b368d.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iWRxniYQx307i3g_KmpA9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/681def478f12e96d03f36ecb564b368d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-24-week-phase-050000342.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-24-week-phase-050000342.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]